Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

87.30
+1.131.31%
Post-market: 88.401.10+1.26%18:10 EDT
Volume:1.14M
Turnover:98.91M
Market Cap:17.05B
PE:19.99
High:87.48
Open:85.65
Low:85.55
Close:86.17
52wk High:92.86
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.50
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:4.09
PE(LYR):554.37

Loading ...

RBC Capital Remains a Hold on Incyte (INCY)

TIPRANKS
·
Oct 09

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Oct 09

Incyte May Face Long-Term Revenue Erosion on Generic Competition, Oppenheimer Says

MT Newswires Live
·
Oct 08

Press Release: Incyte to Report Third Quarter Financial Results

Dow Jones
·
Oct 08

Oppenheimer Downgrades Incyte to Market Perform From Outperform, Price Target is $82

MT Newswires Live
·
Oct 08

Incyte downgraded to Perform from Outperform at Oppenheimer

TIPRANKS
·
Oct 08

U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals

Reuters
·
Oct 08

Incyte : Oppenheimer Cuts to Perform From Outperform

THOMSON REUTERS
·
Oct 08

Top Incyte Executive Cashes In on Stock Sale!

TIPRANKS
·
Oct 07

Incyte EVP & General Counsel Sheila A. Denton Reports Disposal of Common Shares

Reuters
·
Oct 07

Incyte Corp - Appoints Thomas Tray as Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
Oct 04

Incyte Corporation Appoints Thomas Tray as Principal Financial Officer Effective September 2025

Reuters
·
Oct 04

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 30

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

GlobeNewswire
·
Sep 28

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Sep 26

BRIEF-Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Sep 25

Incyte Corporation Files Initial Statement of Beneficial Ownership for EVP, Chief Strategy Officer David H. Gardner

Reuters
·
Sep 25

Incyte Corporation Grants New Executive David H. Gardner Equity Awards Under 2024 Inducement Stock Incentive Plan

Reuters
·
Sep 25

Incyte's CALR Antibody Update May Offer Solid Data But Headwinds Expected, RBC Says

MT Newswires Live
·
Sep 24

Incyte Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Sep 24